10x Genomics has flipped the script in one week — the stock is up 21% to $45.79, shorts are actively covering, and the rally has now blown past every analyst price target on the Street.
The most striking development is the shift in short positioning. A week ago, the previous note flagged shorts grinding higher even as analysts raised targets. That dynamic has reversed sharply. Short interest has fallen 15.7% over the past week to 15.6% of the free float — from roughly 22.7 million shares on July 9 to 18.2 million by July 14. That is a meaningful cover, and the timing maps cleanly onto the price surge: shorts who built into the mid-$30s are now nursing losses approaching 30% on those positions. Despite the elevated float percentage, the borrow market shows no stress — cost to borrow is just 0.46%, barely changed on the week. Availability is generous at 457% of outstanding short interest, meaning there is no mechanical squeeze pressure forcing covers. The retreat looks voluntary rather than structural.
Options traders read the same signal. The put/call ratio has dropped to 0.23, nearly 1.7 standard deviations below its 20-day average of 0.28 — the most call-heavy reading in weeks. That is the opposite of defensive positioning. Traders chasing the breakout are buying calls, not hedging with puts, and the ratio is now approaching the lower end of its 52-week range.
The Street is scrambling to keep up. Canaccord Genuity lifted its target from $32 to $50 on July 14 — the most aggressive move yet, and the only target now sitting above the current price. Morgan Stanley went from $22 to $37, still below $45.79. Citigroup's $45 target, set just a week ago, is already in the rearview. Every firm has raised numbers in recent weeks, but the stock has outrun them all. The consensus mean sits around $37 — more than 15% below where shares are trading now. The bull case centres on Chromium volume acceleration and a 5-19x consumables growth runway per platform by 2027. Bears point to the 90%-plus decline from 2021 peaks, persistent pricing pressure, and no meaningful revenue recovery expected before 2027. That debate has not resolved — but short-term momentum has clearly shifted to the bulls. Compared to close peers, TXG's outperformance is stark: ILMN was flat on the week, PACB fell 3.8%, and BRKR gained just 2.7% — none came close to TXG's 21% move.
One flag worth noting: insiders have been consistent sellers into the rally. CEO Serge Saxonov sold approximately 30,000 shares across multiple transactions in late June at prices between $33 and $36. The Chief Scientific Officer and CFO also sold in May. The net insider position over the past 90 days is a sale of roughly $2.8 million in aggregate. These look like pre-planned programme sales rather than emergency exits, but the pace of selling has not slowed as the stock has risen.
The next earnings event is August 7. The two most recent prints produced next-day declines of 3.5% and 5%, with five-day losses of 9.7% and 5.4% respectively — a consistent pattern of selling the news even when the setup looked constructive. With the stock now trading well above consensus targets and shorts actively covering, how that August print lands will determine whether this week's breakout holds or becomes the next fade.
See the live data behind this article on ORTEX.
Open TXG on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
